Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long [Yahoo! Finance]
Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.